Asian Spectator


The Times

.

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
  • UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-librarytelegram下载betwoonbetgarantizlibrary.jojobetสล็อตสล็อตcasibomstakejojobetStreamEastStreamEasthitbet girişbetasuscasibomjojobetcasino siteleriPadişahbetPadişahbetDizipalStreamEastPadişahbetGalabetmostbetjojobetjojobetcasibommeritkinghttps://chantilly-montessori-school.vercel.app/jojobetgrandpashabetgrandpashabetgrandpashabet